NASDAQ:PPBT

Purple Biotech Stock Predictions

Healthcare > Biotechnology

Buy PPBT

*Your capital is at risk

$1.75

-0.0200 (-1.13%)

At Close: Jun 24, 2026

Currently predicting for Thu, 25 Jun 2026

PPBT Live board

Community Bull/Bear

Target Next close

Join the PPBT prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

PPBT Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For PPBT

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

PPBT Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT PURPLE BIOTECH LTD.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
NESR $25.06	0.439%	Jun 22
IDYA $28.98	25.19%	Jun 12
PHM $118.49	14.53%	Jun 10
DHI $146.71	13.50%	Jun 10
EAT $140.46	20.94%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by